AIHW Board AIHW senior staff Annual report Capability statement Collaboration AIHW corporate plan 2016–17 to 2019–20 Customer care charter FOI - freedom of information Indexed list of files Nous review Organisation chart Presentations Privacy of data Public Interest Disclosure Tenders
By category Ageing, disability & carers Families & children Hospitals Housing & homelessness Indigenous Australians Population groups Risk factors, diseases & death Services, workforce & spending
By subject Adoptions Aged care Ageing Alcohol & other drugs Arthritis & musculoskeletal conditions Asthma Australia's health Australia's welfare Burden of disease Cancer Cardiovascular disease Child health, development & wellbeing Child protection Children's services Chronic diseases
Chronic kidney disease Chronic respiratory conditions COPD Deaths Dementia Dental & oral health Diabetes Disability Expenditure Eye health Food & nutrition Health indicators Health performance Homelessness Hospitals Housing assistance Indigenous Australians Injury Life expectancy
Male health Mental health Mothers & babies Overweight & obesity Palliative care Population health Primary health care Prisoner health Risk factors Rural health Safety & quality of health care Veterans' health Workforce Youth health & wellbeing Youth justice
In other sections Data Publications Contact AIHW
Publications CatalogueOrdering publicationsForthcoming publications Online reports Subscribe to release notices
By subject Adoptions Aged care Ageing Alcohol & other drugs AIHW annual reports Arthritis & musculoskeletal conditions Asthma Australia's health Australia's welfare Burden of disease Cancer Cardiovascular disease Child health, development & wellbeing Child protection Children's services Chronic diseases Chronic kidney disease
Chronic respiratory conditions Corporate publications Data linkage Data standards Deaths Dental & oral health Diabetes Disability Expenditure Eye health Food & nutrition General practice Health indicators Health performance Homelessness Hospitals Housing assistance Indigenous Australians Indigenous housing
Injury Life expectancy Male health Mental health services Mothers & babies Overweight & obesity Palliative care Population health Primary health carePrisoner health Risk factors Rural health Safety & quality of health care Veterans' health Workforce Youth health & wellbeing Youth justice
In other sections Subjects Data Contact AIHW
About AIHW data METeOR—metadata online registry Data by subject AIHW data collections Customised data analysis request Data governance framework Data linking Data standards GovHack Privacy of data Accessing Australian Government health and welfare data
By subjectAboriginal and Torres Strait Islander Health Performance Framework Adoptions Aged care Alcohol and other drugs Alcohol data sources Body weight data sources Cancer Children's headline indicators (CHI) Child protection Data sources for monitoring health conditionsDeaths Diabetes Disability
Expenditure FHBH - Fixing houses for better health General Record of Incidence of Mortality (GRIM) books Height and weight data sources Hospitals Indigenous Australians International collaboration Maternity Information Matrix (MIM) Medical indemnity Mental health Mortality Over Regions and Time (MORT) books National Aged Care Data Clearinghouse
National core maternity indicators (NCMI) National framework for protecting Australia’s children (NFPAC) National indicator catalogue National Youth Information Framework (NYIF) Perinatal data Primary Health Network (PHN) Specialist Homelessness Services (SHS) Tobacco data sources Workforce
In other sections Subjects Publications Contact AIHW
AACR ACFADD AHSAC AIHW Board AIHW Ethics Committee AODTS NMDS WG CKDMAC CMAG CVDMAC HEAC
IGIHM JJ RIG MHISSC NAGATSIHID NCSIMG NDDWG NDIMG NHISSC NIAG NIRAPIMG NMDDNMDS
NMHPSC NOPSAD NPDDC NPHEP NPHIC PCDWG PDWG PHIDG PHIG REDWG Workforce committees
Education worksheets Infographics What's in the pipeline Subscribe to education notices Other educational links
Resources by subject All Latest Ageing Australia's health Australia's welfare Carers
Children & youth Disability Disease Drugs
Health Health prevention Indigenous Australians Injury
In other sections Subjects Data Publications Contact AIHW
Job vacancies How to apply for a position at the AIHW Conditions of employment Benefits of working for the AIHW Temporary employment register Occupational Training Program Contact the People Unit Graduates
AIHW Access magazine Media releases Subscribe to release notices Embargoed access to AIHW material Media contacts
You are here:
Cancer is a group of several hundred diseases in which abnormal cells are not destroyed naturally by the body but instead multiply and spread out of control. Cancers are distinguished from each other by the specific type of cell involved and the place in the body in which the disease began.
Cervical cancer affects the cells of the uterine cervix, which is the lower part (or 'neck') of the uterus where it joins the inner end of the vagina. Cervical cancer develops when abnormal cells in the lining of the cervix begin to multiply out of control and form precancerous lesions. If undetected, these lesions can develop into tumours and spread into the surrounding tissue.
Worldwide, cervical cancer is the fourth most common cancer affecting women and the seventh most common cancer overall; however, the burden of cervical cancer is not equal globally-around 85% of the global burden occurs in the less developed regions, where cervical cancer accounts for almost 12% of all female cancers . In contrast, in Australia cervical cancer accounts for less than 2% of all female cancers, with a relatively low incidence of 7 new cases per 100,000 women .
women (56%) aged 20–69 had a Pap test in the last 2 years.
It has been recognised for some time that cervical cancer is a rare outcome of persistent infection with one or more oncogenic (cancer-causing) types of human papillomavirus (HPV) [2, 8]. These oncogenic types of HPV are known as 'high-risk' HPV, and infection with one or more of these is the underlying cause of almost all cases of cervical cancer. Currently 15 high-risk types of HPV are recognised. HPV types 16, 18, and 45 are most predominantly associated with cervical cancer, with HPV types 16 and 18 detected in 70–80% of cases of cervical cancer in Australia .
However, infection with one or more of the 40 genital HPV types is extremely common, with infection rates of this sexually transmitted infection peaking in women in young adulthood (the period following sexual debut). Most HPV infection is asymptomatic and cleared by the immune system within a year; however, in up to 10% of women the infection can persist, and in a very small number of women, persistent infection with high-risk HPV may eventually lead to cervical cancer.
The 4 major steps in cervical cancer development are infection with HPV (from sexual activity), viral persistence (most HPV infections clear with no treatment), progression to precancerous abnormalities (many of which will also regress with no treatment) and invasive cervical cancer . Note that this is not unidirectional, and that most HPV-infected cells return to normal and a large proportion of precancerous abnormalities do not progress to cervical cancer, even in the absence of treatment.
Infection of cervical cells with high-risk HPV interferes with the normal functioning of these cells, leading to abnormalities in the cells that we recognise as precancerous changes.
However, while the cell changes caused by persistent infection with HPV are necessary for the development of precancerous changes to the cervix, there are a range of other factors that will influence whether precancerous changes will progress to cervical cancer, including smoking; multiparity (specifically more than 5 full-term pregnancies); a young age at first full-term pregnancy; oral contraceptive use; and immunosuppression .
The role HPV plays in the development of cervical cancer allows for the implementation of both primary and secondary strategies for the prevention of cervical cancer, in those countries that have available resources to make cervical cancer prevention a priority.
In Australia, primary prevention of cervical cancer is through vaccination against HPV through the National HPV Vaccination Program to prevent women being infected with high-risk HPV types 16 and 18. Secondary prevention of cervical cancer is through cervical screening through the National Cervical Screening Program to detect and treat abnormalities while they are in the precancerous stage, before any possible progression to cervical cancer. This is possible because cervical cancer is one of the few cancers that has a precancerous stage that lasts for many years prior to the development of invasive disease, which provides an opportunity for detection and treatment .
Detection of precancerous abnormalities through cervical screening uses cytology from the Papanicolaou smear, or 'Pap test', as the screening tool. During a Pap test, cells are collected from the transformation zone of the cervix—the area of the cervix where the squamous cells from the outer opening of the cervix and glandular cells from the endocervical canal meet. This is the site where most cervical abnormalities and cancers are detected.
Detecting precancerous changes to cells allows for intervention before cervical cancer develops, so high participation in cervical screening reduces both an individual's risk and the incidence and burden of cervical cancer in Australia overall.
It is also important to recognise that some cervical cancers do not have a precancerous stage, and therefore are simply unable to be detected by cervical screening. These tend to be rare but aggressive cancers such as neuroendocrine cancer of the cervix, the two most aggressive types being small cell neuroendocrine carcinoma and large cell neuroendocrine carcinoma, neither of which appear to possess a preinvasive stage .
The National Cervical Screening Program aims to reduce cervical cancer cases as well as illness and death resulting from cervical cancer through an organised approach to cervical screening aimed at detecting and treating high-grade abnormalities before possible progression to cervical cancer. More women having regular Pap tests means that more of the serious diseases that can lead to cervical cancer can be found and treated. This leads to fewer cases of cervical cancer, and fewer women dying from this disease.
The National Cervical Screening Program recommends Pap tests every two years for women aged 18–20 or over who have ever been sexually active—including women who have been vaccinated against HPV.
For more information on the National Cervical Screening Program, and for the latest cervical screening data, see the latest Cervical screening in Australia report.
For more information on the National Cervical Cancer Screening Program visit www.cancerscreening.gov.au.